HBM Holdings Limited (HKG:2142)
13.21
+0.15 (1.15%)
Oct 30, 2025, 4:08 PM HKT
HBM Holdings Revenue
HBM Holdings had revenue of $101.32M USD in the half year ending June 30, 2025, with 147.13% growth. This brings the company's revenue in the last twelve months to $115.71M, up 60.25% year-over-year. In the year 2024, HBM Holdings had annual revenue of $38.10M, down -57.43%.
Revenue (ttm)
$115.71M
Revenue Growth
+60.25%
P/S Ratio
12.05
Revenue / Employee
$632.32K
Employees
183
Market Cap
10.95B HKD
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 38.10M | -51.40M | -57.43% |
| Dec 31, 2023 | 89.50M | 48.84M | 120.13% |
| Dec 31, 2022 | 40.66M | 36.35M | 843.80% |
| Dec 31, 2021 | 4.31M | -9.80M | -69.46% |
| Dec 31, 2020 | 14.11M | 8.69M | 160.32% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| JD Health International | 71.34B |
| BeOne Medicines AG | 35.81B |
| Sino Biopharmaceutical | 33.49B |
| Alibaba Health Information Technology | 32.81B |
| CSPC Pharmaceutical Group | 28.49B |
| WuXi Biologics | 21.98B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| Innovent Biologics | 12.52B |